Austrian Registry for Evaluation of Treatment Patterns and Outcome in Patients With Advanced Pancreatic Ductal Adenocarcinoma (PDAC)

This is an Austrian patient registry — not a treatment study — that collects information about how advanced pancreatic cancer (pancreatic ductal adenocarcinoma, or PDAC) is treated in real-world clinical practice and what outcomes patients experience. **You may be eligible if...** - You are 18 or older - You have a confirmed diagnosis of locally advanced, inoperable, or metastatic pancreatic ductal adenocarcinoma - You are starting first-line palliative chemotherapy (platinum- or gemcitabine-based regimens, or nal-irinotecan/5-FU/leucovorin) - You are in reasonably good functional health (ECOG 0–2) - You have given or are willing to give informed consent (not required for retrospective data collection) **You may NOT be eligible if...** - Your pancreatic cancer could be surgically removed and you are not receiving palliative chemotherapy - You have borderline resectable disease and are not receiving palliative chemotherapy Talk to your doctor to see if this trial is right for you.